VG Health

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Barclays Offers Structured Notes Linked to UnitedHealth Group Stock

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO

ETON

IBBQ

LABU

SBIO

ARKG

Eton Pharmaceuticals has secured exclusive U.S. rights to IMPAVIDO, the only FDA-approved oral therapy for leishmaniasis, set for launch on September 26, 2026. This agreement enhances Eton's rare-disease portfolio, which includes ten marketed products and four in late-stage development. CEO Sean Brynjelsen emphasized IMPAVIDO's critical role in their orphan-focused model. Eton's stock closed at $32.89, up 1.23%, and rose to $33.91 in after-hours trading.

nasdaq

Eton Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

SPDR S&P Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Nasdaq

CYTK

CYTK: MYKORZO (aficamten) has received approval for oHCM in the US, EU, and China, with early sales exceeding expectations. Trials indicate strong efficacy and safety. The company is expanding its indications and global launches, with significant physician uptake and patient persistency. European expansion is in progress, and management anticipates minimal impact from MFN.

TradingView

Cytokinetics

iShares Global Healthcare

Key facts: Aficamten approved US, EU, China; launch outpaces targets

PHAR

Pharming Group N.V. reported Q1 2026 revenue of $72.4 million, an 8% decline, primarily due to RUCONEST. However, full-year guidance remains intact at $405-$425 million. Joenja showed strong growth with a 34% revenue increase to $14.1 million. The company maintains positive cash flow and a solid balance sheet with $171.8 million in cash. Despite short-term pressures on RUCONEST, management is optimistic about recovery in 2026, supported by a robust pipeline and regulatory advancements for Joenja.

Tip Ranks

Pharming Group NV

Pharming Group Balances Near-Term Strain With Joenja Growth

KPTI

Karyopharm Therapeutics (KPTI) reported Q1 earnings, highlighting strong Phase III data from the SENTRY trial, which showed significant spleen volume reduction and overall survival benefits. Despite a 17% revenue increase to $35.1 million, the company faces competitive pressures and a limited cash runway, with $91.2 million on hand. Management remains optimistic about potential market opportunities in myelofibrosis and endometrial cancer, while acknowledging challenges from new competitors affecting XPOVIO sales.

Karyopharm Therap

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

ROIV

Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average target increased from $35.71, with estimates ranging from $29.5 to $41 per share. The consensus rating remains 'Buy' from 13 analysts, including 12 Buys and 1 Hold.

Roivant Sciences

Factset Research

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside

HIMS

HIMZ

HIMY

Hims & Hers Health CFO Oluyemi Okupe sold 7,950 shares at $23.64 each, totaling $187,938, reducing his holdings by 2.93%. Post-sale, he owns 262,954 shares valued at approximately $6.22 million. This transaction was part of a pre-arranged trading plan and disclosed to the SEC. The company's stock has seen fluctuations, with recent earnings missing estimates and a market cap of $5.12 billion.

Market Beat

Hims & Hers Health

SPDR S&P Health

iShares US Healthcare Providers

Defiance Daily Target 2X Long HIMS ETF

Defiance Leveraged Long +Income HIMS ETF

Eli Lilly

Novo Nordisk AS

Bank of America

UBS Group AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

RNXT

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

RenovoRx

SPDR S&P Health Equip

iShares US Medical Devices

RenovoRx Earnings Call Signals Commercial Inflection

510660

Antengene Corporation has appointed Dr. Bing Hou as Chief Scientific Officer to enhance its R&D strategy and advance its next-generation therapeutic pipeline. Dr. Hou, who has been with Antengene since 2019, will lead efforts in Drug Discovery and Translational Medicine. His leadership is expected to strengthen the company's proprietary platforms, including the AnTenGager® T-cell engager platform, and support the development of innovative therapies for autoimmune diseases and cancers.

PR Newswire

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

ANTENGENE-B

UCB S.A.

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

BBIO

BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).

Bridgebio Pharma

Direxion S&P Biotech Bear 3X

Citigroup

JPMorgan Chase

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BridgeBio Pharma (BBIO) Gets a Hold from Citi

MRVL

SNDK

QCOM

Marvell Tech(MRVL) rose 4.34%, with a trading turnover 4.3 Billion USD, and a year-to-date rose 107.7%. Sandisk(SNDK) rose 3.77%, with a trading turnover 17.8 Billion USD, and a year-to-date rose 482.7%. Vertiv(VRT) fell 5.03%, with a trading turnover 2.9 Billion USD, and a year-to-date rose 99.2%. BlackRock(BLK) fell 4.57%, with a trading turnover 1.1 Billion USD, and a year-to-date fell 2.6%.

- The Nasdaq Composite Index decreased by 0.84%, with a year-to-date gain of 11.3%.  
- Meanwhile, the S&P 500 fell by 0.67% and the Dow Jones dropped by 0.65%, recording year-to-date increases of 7.4% and 2.7%, respectively.  
- Notable stock movements include Marvell Technology rising by 4.34% and Sandisk increasing by 3.77% year-to-date, while Vertiv and BlackRock saw declines of 5.03% and 4.57%.

Top Gainers&Losers

Marvell Tech

Sandisk

Mizuho Financial

Vertiv

BlackRock

Newmont

Qualcomm

AppLovin

Top 5 US Stock Gainers/Losers (>100B) (5.19)

DVAX

VXRT

Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.

Dynavax Tech

Vaxart

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027

VG Health(VHT.US)